AUTHOR=Larrañaga Igor , Mar Javier , Gorostiza Ania , García-Lorenzo Borja , Zubeltzu Beñat , Vega Remedios , Kaye Rachelle , Levy Gil , Vishnevetsky Olga , Lyngholm Christensen Rikke , Dichmann Sorknæs Anne , Garton Natassia , Swoboda Anne , Arndt Fritz , McCann Lisa , Maguire Roma , Miller Morven , Laleci Erturkmen Gokce B. , Yuksel Mustafa , Arvanitis Theodoros N. , Tong Chao , Aznar-Baranda Jose I. , Caballero Jessica , González Nerea , de la Torre Juan , Verdoy Dolores , de Manuel Keenoy Esteban , Fullaondo Ane ,  ADLIFE Consortium , Ortega-Gil Ana , Moro Ángel , Alayo Itxaso , Aguirre Urko , López Bárbara , Kalra Dipak , Gröne Oliver , Blömeke-Cammin Janika , Lilja Mikael , Robbins Tim , Juul Natassia K. , Morton Alec , Koutsouradis Konstantinos , Sarigul Bunyamin , Yilmaz Gokhan , Pournik Omid , Panchal Shramika , Peake Ashley 

TITLE=Evaluation of the epidemiological and economic impact of the ADLIFE intervention on medium- to long-term in patients with advanced chronic disease

JOURNAL=Frontiers in Public Health

VOLUME=Volume 13 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1682492

DOI=10.3389/fpubh.2025.1682492

ISSN=2296-2565

ABSTRACT=IntroductionPatients with advanced chronic disease (ACD) experience transitions in their clinical stability, leading to increased healthcare resource use and costs. EU-funded ADLIFE digital intervention aimed to ensure their quality of life through individualised care plans, clinical decision-making support, and patient empowerment. This study assessed the impact and sustainability of ADLIFE.Materials and methodsTarget population included patients aged ≥55 years with heart failure (HF) and/or chronic obstructive pulmonary disease (COPD). First, a discrete event simulation (DES) model was developed using data from Osakidetza-Basque Health Service to represent the natural history of the disease. Second, ADLIFE intervention was implemented in four pilot sites: Spain, England, Israel and Denmark. Intervention effect was quantified by comparing resource use between control and intervention groups. Finally, a budget impact analysis (BIA) was conducted by extrapolating the burden of the disease to 2030 under two scenarios: conventional and ADLIFE.ResultsADFLIFE intervention involved 370 patients (185 intervention, 185 control). Emergency visits and consultations with primary care professionals decreased significantly, while specialist consultations increased. Depending on the pilot site, projections estimated that ACD prevalence will increase by 37–50% by 2030, increasing associated costs. Under the ADLIFE scenario, the burden of the disease could be reduced by 1–2%, resulting in cumulative savings of €4–58 million.DiscussionProjections indicated a major challenge ahead due to a rise in ACD prevalence, highlighting the need for timely and effective healthcare responses. ADLIFE improved patient care and resource management, and its adoption could help reduce the disease burden and generate sustained long-term savings.